Translational advances in pancreatic ductal adenocarcinoma therapy

Authors

Abdel Nasser Hosein, Advocate Aurora HealthFollow
Stephanie K. Dougan, Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. stephanie_dougan@dfci.harvard.edu.
Andrew J. Aguirre, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. andrew_aguirre@dfci.harvard.edu.
Anirban Maitra, Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. amaitra@mdanderson.org.

Recommended Citation

Hosein AN, Dougan SK, Aguirre AJ, Maitra A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer. 2022;3(3):272-286. doi:10.1038/s43018-022-00349-2

Affiliations

Advocate Aurora Health, Vince Lombardi Cancer Clinic, Sheboygan, WI

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently detected at advanced stages, limiting treatment options to systemic chemotherapy with modest clinical responses. Here, we review recent advances in targeted therapy and immunotherapy for treating subtypes of PDAC with diverse molecular alterations. We focus on the current preclinical and clinical evidence supporting the potential of these approaches and the promise of combinatorial regimens to improve the lives of patients with PDAC.

Document Type

Article

PubMed ID

35352061